Deep tech startup developing a groundbreaking molecule matching solution for drug discovery.
Aqemia raises €30 million in a Series A funding round led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of Elaia its historic investor. This financing will further support Aqemia’s core mission: to massively scale drug discovery, through a first-in-class technological platform combining quantum- inspired physics and machine learning.
2022.10.19 / 4min read.
Aqemia, a deeptech startup that leverages artificial intelligence (AI) and quantum-inspired physics for drug discovery, announced today an agreement with the pharmaceutical company Sanofi to contribute to the discovery of effective treatments for COVID-19.
2020.12.10 / 4min read.
Dr. Jean-Marc Herbert, ex Vice-President Discovery at Sanofi, will provide his experience in drug discovery to support Aqemia’s rapid growth in the field.
His strategic advice will range from selecting therapeutic targets & projects and building the best model to address drug discovery challenges, to navigating through the Large Pharma ecosystem.
2020.07.08 / 3min read.
Sacha Loiseau, Ph.D., Venture Partner at Elaia declares: “Aqemia’s technology to predict affinity between drug candidates and therapeutic targets has the clear potential to change the drug discovery paradigm and to thus have a major impact on the success rate of the entire drug development process. This is in strong adequation with Elaia’s strategy for the PSL Innovation Fund to invest in early-stage companies with disruptive technologies. We’re excited to be the first investor backing Aqemia and look forward to what lies ahead.”
2019.10.17 / 2min read.